Uroxatral: Targeted Relief for Enlarged Prostate Symptoms
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.23 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $104.47 $85.38 (18%) | 🛒 Add to cart |
| 90 | $1.32 | $156.70 $118.53 (24%) | 🛒 Add to cart |
| 120 | $1.21 | $208.94 $144.65 (31%) | 🛒 Add to cart |
| 180 | $1.10 | $313.41 $198.89 (37%) | 🛒 Add to cart |
| 270 | $1.00 | $470.11 $271.22 (42%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $626.81 $325.46 (48%) | 🛒 Add to cart |
Synonyms | |||
Uroxatral (alfuzosin HCl) is a clinically proven, selective alpha-1 blocker specifically designed to manage the urinary symptoms associated with benign prostatic hyperplasia (BPH). By relaxing the smooth muscle in the prostate and bladder neck, it facilitates improved urine flow and reduces obstruction, offering significant relief from bothersome lower urinary tract symptoms. This medication represents a first-line pharmacological approach for men seeking to regain control over urinary function and improve quality of life without immediate surgical intervention. Its selective mechanism allows for effective symptom management with a tailored side effect profile.
Features
- Contains alfuzosin hydrochloride as the active ingredient
- Available in 10 mg extended-release tablets
- Selective alpha-1 adrenergic receptor antagonist
- Designed for once-daily dosing
- Formulated with a unique extended-release delivery system
- FDA-approved for the treatment of symptomatic BPH
Benefits
- Significantly improves urinary flow rate and reduces hesitancy
- Decreases the frequency and urgency of urination, especially at night
- Reduces the sensation of incomplete bladder emptying
- Helps prevent acute urinary retention episodes
- Enhances overall quality of life by minimizing BPH-related discomfort
- Provides targeted action with minimal effect on blood pressure when used as directed
Common use
Uroxatral is primarily prescribed for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in adult men. This condition, characterized by non-cancerous enlargement of the prostate gland, commonly leads to obstructive and irritative urinary symptoms including weak stream, straining, dribbling, nocturia (frequent urination at night), urgency, and hesitancy. It is not indicated for use in women or children, and should not be used for the treatment of hypertension.
Dosage and direction
The recommended dosage of Uroxatral is one 10 mg extended-release tablet taken orally once daily, immediately after the same meal each day. Tablets should be swallowed whole and not crushed, chewed, or divided. The medication should be taken at approximately the same time each day to maintain consistent blood levels. Dosage adjustment is not typically required for elderly patients or those with renal impairment, but caution is advised in patients with hepatic impairment. Treatment response is usually evident within weeks, but maximum benefit may require several months of continuous therapy.
Precautions
Prior to initiating Uroxatral therapy, patients should undergo a thorough medical evaluation to rule out prostate cancer. Orthostatic hypotension (a sudden drop in blood pressure when standing up) may occur, especially during initial treatment or dose increases. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks until they know how Uroxatral affects them. Those with severe renal or hepatic impairment should use Uroxatral with caution. Regular monitoring of blood pressure is recommended, particularly during the initial phase of treatment. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.
Contraindications
Uroxatral is contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride or any component of the formulation. It should not be used in patients with moderate to severe hepatic impairment (Child-Pugh categories B and C). Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, and other potent inhibitors is contraindicated. Uroxatral is not indicated for use in women or children, and should not be administered to patients with a history of orthostatic hypotension.
Possible side effects
Common side effects may include dizziness (6-19%), headache (3-11%), fatigue (4-8%), and upper respiratory tract infection (3-5%). Less frequently, patients may experience orthostatic hypotension, tachycardia, nausea, abdominal pain, or impotence. Rare but serious side effects include priapism (prolonged and painful erection requiring immediate medical attention), syncope (fainting), and severe allergic reactions. Most side effects are mild to moderate and often diminish with continued therapy. Patients should report any persistent or bothersome side effects to their healthcare provider.
Drug interaction
Uroxatral is primarily metabolized by CYP3A4 enzymes and may interact with medications that inhibit this pathway. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) is contraindicated. Caution is advised when using Uroxatral with other alpha-blockers, phosphodiesterase-5 inhibitors, antihypertensives, or nitrates due to potential additive blood pressure-lowering effects. Moderate CYP3A4 inhibitors (erythromycin, diltiazem) may increase alfuzosin concentrations and should be used with caution. Patients should inform their healthcare provider about all prescription and non-prescription medications they are taking.
Missed dose
If a dose of Uroxatral is missed, it should be taken as soon as remembered on the same day, with food. If the missed dose is not remembered until the next day, the patient should skip the missed dose and resume the regular dosing schedule. Double doses should not be taken to make up for a missed dose. Maintaining a consistent dosing routine with meals helps optimize the medication’s absorption and effectiveness while minimizing potential side effects.
Overdose
In case of suspected overdose, supportive care should be initiated with particular attention to maintaining blood pressure and heart rate. Expected manifestations would primarily include severe hypotension requiring active cardiovascular support. Patients should be placed in a supine position with legs elevated, and intravenous fluids should be administered. Vasopressors may be required, but care should be taken to avoid exacerbating hypotension. Dialysis is unlikely to be beneficial due to high protein binding. Symptomatic treatment should be provided while monitoring vital signs closely. Any suspected overdose requires immediate medical attention.
Storage
Uroxatral tablets should be stored at room temperature (20-25°C or 68-77°F) in their original container, protected from light and moisture. Keep the medication out of reach of children and pets. Do not store in bathrooms or other areas with high humidity. Properly discard any expired or unused medication through medication take-back programs or according to FDA-recommended disposal methods. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Uroxatral is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and not all patients will experience the same benefits or side effects. Patients should consult with their healthcare provider for personalized medical advice, diagnosis, and treatment recommendations. Never disregard professional medical advice or delay seeking it because of something you have read in this product information.
Reviews
Clinical studies demonstrate that Uroxatral provides significant improvement in IPSS (International Prostate Symptom Score) with a mean reduction of 5-7 points from baseline. Patients report particular satisfaction with reduced nocturia and improved flow metrics. Many urologists note its favorable side effect profile compared to non-selective alpha-blockers, with one study showing only 0.6% of patients discontinuing due to dizziness. Long-term extension studies confirm maintained efficacy over 24 months of treatment with sustained quality of life improvements. Real-world evidence supports its position as a well-tolerated option for men seeking pharmacological management of BPH symptoms.